ArticlePharmaceutical research2019
E-Jet 3D-Printed Scaffolds as Sustained Multi-Drug Delivery Vehicles in Breast Cancer Therapy.
Article in Pharmaceutical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Decoding triple negative breast cancer bone metastasis: from 3D bioprinted models to clinical translation.Journal of nanobiotechnology · 2026Review
- 3D Printing in Oral Drug Delivery: Technologies, Clinical Applications and Future Perspectives in Precision Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Nanocarrier-mediated cancer therapy with cisplatin:Heliyon · 2024Article
- Excipients in Pharmaceutical Additive Manufacturing: A Comprehensive Exploration of Polymeric Material Selection for Enhanced 3D Printing.Pharmaceutics · 2024Review
- Tissue engineering strategies for breast reconstruction: a literature review of current advances and future directions.Annals of translational medicine · 2024Review
- 3D-printed nanomedicines for cancer therapy.Future science OA · 2024Article
- 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals.Pharmaceutics · 2023Review
- 3D and 4D Printing in the Fight against Breast Cancer.Biosensors · 2022Review
- Fundamental investigation of sustained and controlled therapeutics release from 3D printed medical devices.Materials today. Chemistry · 2022Article
- Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2022Review
- 3D printing of pharmaceuticals for disease treatment.Frontiers in medical technology · 2022Review
- 3D-Printed Coaxial Hydrogel Patches with Mussel-Inspired Elements for Prolonged Release of Gemcitabine.Polymers · 2021Article
- Three-Dimensional Printing for Cancer Applications: Research Landscape and Technologies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Recent Advances in 3D Printing for Parenteral Applications.The AAPS journal · 2021Review
- 3D printedTheranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeCombination chemotherapy is gradually receiving more attention because of its potential synergistic effect and reduced drug doses in clinical application. However, how to precisely control drug release dose and time using vehicles remains a challenge. This work developed an efficient drug delivery system to combat breast cancer, which can enhance drug effects despite reducing its concentration.
methodsControlled-release poly-lactic-co-glycolic acid (PLGA) scaffolds were fabricated by E-jet 3D printing to deliver doxorubicin (DOX) and cisplatin (CDDP) simultaneously.
resultsThis drug delivery system allowed the use of a reduced drug dosage resulting in a better effect on the human breast cancer cell apoptosis and inhibiting tumor growth, compared with the effect of each drug and the two drugs administrated without PLGA scaffolds. Our study suggested that DOX-CDDP-PLGA scaffolds could efficiently destroy MDA-MB-231 cells and restrain tumor growth.
conclusionsThe 3D printed PLGA scaffolds with their time-programmed drug release might be useful as a new multi-drug delivery vehicle in cancer therapy, which has a potential advantage in a long term tumor cure and prevention of tumor recurrence.
Indexed as
Identifiers
31741089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.